Loading
This study tests TROP-2-directed treatment; the registry reports that it is not yet recruiting.
The registry lists NCT06454890 as not yet recruiting, last updated 2024-06-12. Enrolment is 50 planned participants, an estimate. Interventions: Anti-Trop2 CAR-NK cell. Primary measures include Safety by Common Terminology Criteria for Adverse Events (CTCAE) V5.0; Objective Response Rate (ORR). No results are posted in the registry; this does not exclude separate publications.
Shares TROP2, Small-cell lung cancer, Non-small-cell lung cancer.
Shares TROP2, Small-cell lung cancer, Non-small-cell lung cancer.
Shares TROP2, Small-cell lung cancer, Non-small-cell lung cancer.
Shares TROP2, Small-cell lung cancer, Non-small-cell lung cancer.
Shares TROP2, Small-cell lung cancer, Non-small-cell lung cancer.
Shares TROP2, Small-cell lung cancer, Non-small-cell lung cancer.
Shares TROP2, Small-cell lung cancer, Non-small-cell lung cancer.
Shares TROP2, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/